Information  X 
Enter a valid email address

Open Orphan PLC Ord 0.1P (ORPH)

Date Time Source Announcement
13 Oct 2021 7:00 am
RNS
Directorate Change
20 Sep 2021 7:00 am
RNS
Half-year Report
  7:00 am
RNS
�5.7m Influenza human challenge study contract win
09 Sep 2021 7:00 am
RNS
Notice of Results
07 Sep 2021 7:00 am
RNS
Positive results from RSV Human Challenge Study
24 Aug 2021 9:05 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
�8.1m Asthma Human Challenge Study Contract Win
09 Aug 2021 7:00 am
RNS
Malaria Human Challenge Model
29 Jul 2021 7:00 am
RNS
DNDi Phase II trial support
22 Jul 2021 7:00 am
RNS
NEJM Opinion Piece
21 Jul 2021 12:58 pm
RNS
Result of AGM
14 Jul 2021 9:06 am
RNS
Directors' Dealings
  8:04 am
RNS
AIM Schedule 1 update by Poolbeg Pharma plc
  7:01 am
RNS
New Contract win for Open Orphan's Breda office
  7:00 am
RNS
COVID-19 Human Challenge Programme update
09 Jul 2021 7:00 am
RNS
HRV and Flu contract
07 Jul 2021 4:41 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension
30 Jun 2021 7:00 am
RNS
2020 Annual Report and 2021 AGM Notice
17 Jun 2021 7:00 am
RNS
Final Results to 31 December 2020
  7:00 am
RNS
Demerger Update
14 Jun 2021 7:00 am
RNS
Re. Distribution in Specie and Notice of Results
11 Jun 2021 7:00 am
RNS
Exercise of Warrants
19 May 2021 7:00 am
RNS
Court Approval
10 May 2021 7:15 am
RNS
Exercise of Share Options
  7:00 am
RNS
�3m COVID challenge virus manufacturing contract
29 Apr 2021 11:39 am
RNS
Result of General Meeting
13 Apr 2021 7:00 am
RNS
Potential demerger of certain non-core assets
09 Apr 2021 7:00 am
RNS
Launch of Disease in Motion platform
31 Mar 2021 7:00 am
RNS
Holding(s) in Company
26 Mar 2021 7:00 am
RNS
�7.5m Human Challenge Study Contract
25 Mar 2021 7:00 am
RNS
COVID-19 Human Challenge Programme update
11 Mar 2021 7:00 am
RNS
Journal for Clinical Studies article publication
09 Mar 2021 7:00 am
RNS
New contract win with Oxford BioTherapeutics
26 Feb 2021 4:58 pm
RNS
Holding(s) in Company
17 Feb 2021 9:00 am
RNS
Ethics approval - COVID-19 Human Challenge Study
09 Feb 2021 3:57 pm
RNS
Holding(s) in Company
03 Feb 2021 7:05 am
RNS
Exercise of Investor Warrants & TVR
  7:00 am
RNS
New challenge study quarantine clinic
01 Feb 2021 7:00 am
RNS
Contract extension with Carna Biosciences
21 Jan 2021 7:00 am
RNS
Article published in Drug Discovery Today
20 Jan 2021 7:00 am
RNS
Expansion of volunteer recruitment centres
11 Jan 2021 7:00 am
RNS
First volunteer dosed in COVID-19 clinical trial
06 Jan 2021 4:29 pm
RNS
Holding(s) in Company
  7:00 am
RNS
Contract renewal with top-3 pharmaceutical client
31 Dec 2020 7:00 am
RNS
Rule 19.6(c) Confirmation
23 Dec 2020 7:00 am
RNS
Successful completion of toxicology study
22 Dec 2020 7:00 am
RNS
Contract renewal with top-3 pharmaceutical client
14 Dec 2020 7:30 am
RNS
Exercise of Share Options
  7:00 am
RNS
MHRA approval for nasal COVID-19 vaccine trial
07 Dec 2020 7:00 am
RNS
Venn Life Sciences contract wins
24 Nov 2020 7:00 am
RNS
Directors Change
19 Nov 2020 7:00 am
RNS
Collaboration with HIC-VAC and Wellcome Trust
05 Nov 2020 7:00 am
RNS
New �2.5m Influenza Challenge Study Contract Win
30 Oct 2020 11:00 am
RNS
Price Monitoring Extension
  7:10 am
RNS
Exercise of Share Options
  7:00 am
RNS
New 2-year contract with a tier 1 German company
20 Oct 2020 7:00 am
RNS
Contract Signed with UK Government
16 Oct 2020 8:47 am
RNS
Statement re further media comment

a d v e r t i s e m e n t